• DOI:10.1056/NEJMoa1413687
• Corpus ID: 11400976

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

@article{Gali2015InitialUO,
  title={Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.},
  author={Nazzareno Gali{\`e} and Joan Albert Barber{\`a} and Adaani E. Frost and Hossein Ardeschir Ghofrani and Marius M. Hoeper and Vallerie V McLaughlin and Andrew J. Peacock and G{\'e}rald Simonneau and J-L. Vachiéry and Ekkehard Gr{\"u}nig and Ronald J. Oudiz and Anton Vonk-Noordegraaf and R. James White and Christiana Blair and Hunter Campbell Gillies and Karen L. Miller and Julia H N Harris and Jonathan Langley and Lewis J. Rubin},
  journal={The New England journal of medicine},
  year={2015},
  volume={373 9},
  pages={
          834-44
        }
}

• N. Galiè, J. Barberà, +16 authors L. Rubin
• Published 26 August 2015
• Medicine, Psychology
• The New England journal of medicine

BACKGROUND
Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.

METHODS
In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentan-monotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily. The primary end point in a time-to-event analysis was the first event of clinical failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clinical response.

RESULTS
The primary analysis included 500 participants; 253 were assigned to the combination-therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group. A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, respectively, and in 31% of the pooled-monotherapy group (the two monotherapy groups combined). The hazard ratio for the primary end point in the combination-therapy group versus the pooled-monotherapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001). At week 24, the combination-therapy group had greater reductions from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monotherapy group (mean change, -67.2% vs. -50.4%; P<0.001), as well as a higher percentage of patients with a satisfactory clinical response (39% vs. 29%; odds ratio, 1.56 [95% CI, 1.05 to 2.32]; P=0.03) and a greater improvement in the 6-minute walk distance (median change from baseline, 48.98 m vs. 23.80 m; P<0.001). The adverse events that occurred more frequently in the combination-therapy group than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia.

CONCLUSIONS
Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clinical-failure events than the risk with ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and GlaxoSmithKline; AMBITION ClinicalTrials.gov number, NCT01178073.).